Biotech Finance
Stonegate Capital Partners Updates Coverage on Cingulate Inc. Following FDA Complete Response Letter
Cingulate Inc. faces a CMC-driven resubmission process for CTx-1301 after FDA issues Complete Response Letter, but strong cash position and intact product thesis suggest timeline rather than viability is the key concern.
Quantum BioPharma Engages Stocks.news for Investor Relations Services
Quantum BioPharma Ltd. has hired Stocks.news for a six-month, $250,000 investor relations campaign, signaling its commitment to raising market awareness.
Optimi Health Prices $15 Million Public Offering for Nasdaq Uplisting, Aims to Scale Psychedelic Drug Production
Optimi Health Corp. has priced a $15 million public offering as it uplists to the Nasdaq Capital Market, planning to use proceeds to expand production and distribution of its GMP-grade psychedelic drug products for mental health therapies.
Quantum BioPharma Completes Warrant Expiration, Confirms CVR Distribution Date for Potential Litigation Windfall
Quantum BioPharma has finalized the expiration of hedge fund warrants and confirmed the record date for contingent value rights that could provide shareholders with a significant share of potential proceeds from its $700 million litigation.
Helix BioPharma to Present Clinical Trial Progress and NASDAQ Uplisting Plans at Investor Summit
Helix BioPharma will present its Phase Ib/II clinical study for non-small cell lung cancer treatment and planned NASDAQ uplisting at the Q3 2025 Investor Summit, highlighting strategic moves to advance oncology therapies and access global capital markets.
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Treatment Development
Propanc Biopharma has closed a $4 million public offering to fund development of its novel pancreatic proenzyme therapy targeting cancer stem cells in pancreatic, ovarian, and colorectal cancers.
Nutriband Inc. Announces 25% Preferred Stock Dividend Tied to AVERSA Fentanyl FDA Approval
Nutriband Inc. (NASDAQ: NTRB) has declared a 25% preferred stock dividend, contingent on FDA approval of its AVERSA Fentanyl product, highlighting its strategy to enhance shareholder value during the product's commercialization phase.